MedTrace Logo

Pomalidomide as an Immune-enhancing Agent for the Control of HIV

NCT06660498 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-05-07

No results posted yet for this study

Summary

This study is designed to evaluate the safety and efficacy of pomalidomide in HIV-1-infected individuals on ART and to determine the impact of pomalidomide on virological control in people living with HIV during an analytical treatment interruption.

Conditions

  • HIV-1 Infection

Interventions

DRUG

Pomalidomide 2 mg

Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.

DRUG

Placebo

Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.

DRUG

Aspirin 75 mg

Auxiliary Medicinal Product

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Thomas A. Rasmussen, Associate professor, MD, PhD · University of Aarhus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-13
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Australia
  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06660498 on ClinicalTrials.gov